Literature DB >> 9986739

Enhanced tenascin expression associated with reactive astrocytes in human optic nerve heads with primary open angle glaucoma.

J D Pena1, H J Varela, C S Ricard, M R Hernandez.   

Abstract

Tenascin is a large extracellular matrix glycoprotein expressed in neural and non-neural tissues. In the central nervous system, tenascin is synthesized by astrocytes during development and wound healing, forming barriers and affecting neurite outgrowth. In this study we examined tenascin expression in optic nerve heads of normal and glaucomatous eyes and found that there is upregulation of tenascin mRNA and protein in reactive astrocytes from human glaucomatous optic nerve heads compared to normal age-matched controls. In the prelaminar region there was a band of tenascin immunoreactivity around the blood vessels of glaucomatous, but not in normal eyes. However, tenascin mRNA was only localized to astrocytes, suggesting that astrocytes are the cellular source of tenascin. In the lamina cribrosa, tenascin immunoreactivity and gene expression were localized to astrocytes in the cribriform plates and inside the nerve bundles. In the post-lamina region, tenascin immunoreactivity and gene expression were localized to astrocytes lining the pial septum immediately adjacent to the lamina cribrosa. In normal optic nerve heads, tenascin expression at the mRNA and protein levels was confined to clusters of astrocytes at the level of Bruch's membrane in the prelaminar optic nerve head. In glaucoma, enhanced expression of tenascin may be protective to the axons of the retinal ganglion cells by providing a barrier for humoral and/or blood-borne factors that may cause further neural damage. However, the precise role of tenascin in glaucomatous optic neuropathy is not yet elucidated. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9986739     DOI: 10.1006/exer.1998.0577

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  29 in total

Review 1.  Differential gene expression in glaucoma.

Authors:  Tatjana C Jakobs
Journal:  Cold Spring Harb Perspect Med       Date:  2014-07-01       Impact factor: 6.915

Review 2.  Neuroinflammation in glaucoma: A new opportunity.

Authors:  Pete A Williams; Nick Marsh-Armstrong; Gareth R Howell
Journal:  Exp Eye Res       Date:  2017-02-24       Impact factor: 3.467

Review 3.  Tools and resources for analyzing gene expression changes in glaucomatous neurodegeneration.

Authors:  Robert W Nickells; Heather R Pelzel
Journal:  Exp Eye Res       Date:  2015-05-19       Impact factor: 3.467

4.  Hypoxia Activates Calpains in the Nerve Fiber Layer of Monkey Retinal Explants.

Authors:  Masayuki Hirata; Thomas R Shearer; Mitsuyoshi Azuma
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-09       Impact factor: 4.799

5.  Biomarkers of primary open-angle glaucoma.

Authors:  Paul A Knepper; John R Samples; Beatrice Yjt Yue
Journal:  Expert Rev Ophthalmol       Date:  2010-12

6.  Integrins in the optic nerve head: potential roles in glaucomatous optic neuropathy (an American Ophthalmological Society thesis).

Authors:  John C Morrison
Journal:  Trans Am Ophthalmol Soc       Date:  2006

Review 7.  The complex role of neuroinflammation in glaucoma.

Authors:  Ileana Soto; Gareth R Howell
Journal:  Cold Spring Harb Perspect Med       Date:  2014-07-03       Impact factor: 6.915

Review 8.  Primary open-angle glaucoma.

Authors:  Young H Kwon; John H Fingert; Markus H Kuehn; Wallace L M Alward
Journal:  N Engl J Med       Date:  2009-03-12       Impact factor: 91.245

9.  Sub-region-Specific Optic Nerve Head Glial Activation in Glaucoma.

Authors:  Kazuya Oikawa; James N Ver Hoeve; Leandro B C Teixeira; Kevin C Snyder; Julie A Kiland; N Matthew Ellinwood; Gillian J McLellan
Journal:  Mol Neurobiol       Date:  2020-04-07       Impact factor: 5.590

10.  Global changes in optic nerve head gene expression after exposure to elevated intraocular pressure in a rat glaucoma model.

Authors:  Elaine C Johnson; Lijun Jia; William O Cepurna; Thomas A Doser; John C Morrison
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-07       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.